Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telix Pharmaceuticals ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals announced that all resolutions proposed at its Annual General Meeting were successfully passed by shareholders. This outcome reflects shareholder confidence and supports Telix’s strategic direction in the biopharmaceutical industry, potentially enhancing its market position and stakeholder value.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company is dedicated to addressing significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products.
Average Trading Volume: 2,006,483
Technical Sentiment Signal: Buy
Current Market Cap: A$8.7B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.